Skip to main content
Clinical Trials/JPRN-UMIN000032610
JPRN-UMIN000032610
Completed
未知

An exploratory intervention study on the effect of omega-3 fatty acid supplementation for systemic inflammatory response in gastrointestinal cancer patients: A multicenter study. - An exploratory intervention study on the effect of omega-3 fatty acid supplementation for systemic inflammatory response in gastrointestinal cancer patients: A multicenter study.

Mie University0 sites300 target enrollmentMay 17, 2018

Overview

Phase
未知
Intervention
Not specified
Conditions
esophageal cancer, gastric cancer, colorectal cancer
Sponsor
Mie University
Enrollment
300
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 17, 2018
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Patients with metastatic brain disease 2\. Patients with immunological disorders 3\. Patients with severe liver disease. a. Patient diagnosed as cirrhosis. b. Aspartate aminotransferase (AST) 100 U/L (in the case of liver metastasis Over 200 U/L) or more c. Alanine aminotransferase (ALT) 100 U/L (in the case of liver metastasis, 200U/L) or more d. Total bilirubin 2\.0 mg/dL or more 4\. Patients with clotting abnormalities. a. Prothrombin time International standard ratio (PT\-INR) 1\.5 or more (ie, in patients with warfarin, less than PT\-INR 3\.0\) b. Activated partial thromboplastin time (APTT) prolongation of 46 seconds or more 5\. Patients with decreased bone marrow function Hemoglobin less than 8 g/dl, neutrophil count 1000 /ul, platelets 75000 /ul 6\. Patients taking EPA preparations due to underlying diseases 7\.Patients receiving antiplatelets and anticoagulant therapy 8\. Active bleeding lesions other than the target digestive organ cancer. It includes peptic ulcers and trauma. 9\. Patients with ileus, bowel obstruction, or uncontrollable diarrhea 10\. Patients with stroke such as cerebral hemorrhage or subarachnoid hemorrhage or patients with a history within 24 weeks before registration (excluding asymptomatic lacunar infarction) 11\. Allergy to omega3 fatty acid component 12\. Diabetic patients with poor control 13\. Other patients who were judged inappropriate for the doctor

Outcomes

Primary Outcomes

Not specified

Similar Trials